Afatinib Maleate API

Name	Afatinib maleate
Chinese name	马来酸阿法替尼
Cas Number	-
Source	India
Qualifications	USDMF/-/-/-/-

Afatinib maleate is an aniline quinazoline compound developed by Boehringer Ingelheim. Its oral tablet was approved by the U.S. Food and Drug Administration (FDA) in July 2013. Based on the breakthrough results of afatinib maleate in clinical research, it was included in the priority review process of the US Food and Drug Administration (FDA). Afatinib maleate is an irreversible EGFR-HER2 dual tyrosine kinase receptor inhibitor, which can irreversibly bind to EGFR-HER2 tyrosine kinase, inhibit its tyrosine kinase activity, and then block EGFR-HER2 mediated tumor cell signal transduction, inhibits tumor cell proliferation and metastasis, and promotes tumor cell apoptosis. Compared with gefitinib, the relative risk of death or progression of afatinib was reduced by 27%. In another clinical trial, afatinib maleate demonstrated a mOS of 7.9 months which was significantly better than erlotinib's 6.8 months. In 2018, the size of China's EGFR-TKI drug market was 6.52 billion yuan, and it will grow to 18.27 billion yuan by 2023. The compound annual growth rate from 2018 to 2023 is expected to be 22.9%.

Hot Tags: afatinib maleate api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Salmeterol Xinafoate API, Vinpocetine API, Tetrabenazine API, Pazopanib Hydrochloride Pazopanib API, Ulipristal Acetate API, Solinasine Succinate API

• Previous: Diosmin API
• Next: Olanzapine API